We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept


Lesvi's product portfolio comprises CNS pharmaceuticals and nutraceuticals, unique dosage forms and products in other therapeutic areas such as antiemetic, anti-infective, cardiovascular, pain and respiratory diseases.
Product Indication Dosage form Strength
Methocarbamol Muscle spasms, pain Film-coated tablets 500, 750 and 1500 mg
Noxiall® Useful to contrast chronic and neuropathic pain Jan 2017
Olanzapine Psychosis, schizophrenia Film-coated tablets 2.5, 5, 7.5, 10, 15 and 20 mg
Olanzapine Psychosis, schizophrenia Orodispersable tablets 5, 10, 15 and 20 mg
Partnena® Rational combination for the prophylaxis of migraine, the nociceptive modulation and the reduction of tension states Jan 2014
Pramipexol Parkinson's Tablets 0.088, 0.18, 0.35, 0.7 and 1.1 mg
Pregabaline * Neuropathic pain Tablets 25, 50, 75, 100, 150, 200, 225 and 300 mg
Quetiapine * Psychosis, schizophrenia, bipolar disoder Film-coated tablets 25, 50, 100, 150, 200, 300 and 400 mg
Quetiapine * Psychosis, schizophrenia, bipolar disoder Orodispersable tablets 25 and 50 mg
Quetidia® oral solution Useful for the management of anxiety disorders Sep 2017
Rasagiline Parkinson's Tablets 1 mg
Risperidone Psychosis, schizophrenia, bipolar disoder Film-coated tablets 0.5, 1, 2, 3, 4 and 6 mg
Rotigotine Parkinson's Patches 1, 2, 3, 4, 6 and 8 mg/24h
Seripnol® Useful to promote relaxation and sleep Mar 2012
Seripnol® drops Useful to promote relaxation and sleep Apr 2014

Sodium Oxybate Narcolepsy Oral solution 500 mg/ml
Sultiame * Epilepsy, convulsions Film-coated tablets 50, 100 and 200 mg
Tolcapone Parkinson's Film-coated tablets 100 mg
Tranylcypromine Depression Film-coated tablets 10, 20 and 40 mg
Trazodone Depression XR tablets 75 and 150 mg

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.

© Neuraxpharm / LESVI. All rights reserved.